Parnell Announces Results From the Successful Efficacy

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Parnell Announces Results From the Successful Efficacy Study for Zydax(R)

OVERLAND PARK, Kan., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd (Nasdaq: PARN ) today announced the results from a successful, large-scale efficacy study of Zydax, for the treatment of the clinical signs of canine osteoarthritis, or OA. Zydax is intended to stimulate the growth of new cartilage and inhibit cartilage breakdown for the treatment of OA in dogs and horses.

The multi-site, double-blinded, randomized, placebo-controlled pilot study was designed to ascertain the effectiveness of Zydax in reducing pain and interference caused by osteoarthritis in dogs and to determine a prospective clinical endpoint to be used in an upcoming pivotal efficacy study. 140 dogs (94 treated and 46 control) completed the study, which required dog owners to use the Canine Brief Pain Inventory (CBPI) assessment tool. Developed by University of Pennsylvania, the CPBI uses a 10-point scale to score four Pain Criteria and six Interference Criteria. The four pain scores are averaged to provide the Pain Severity Score (PSS), and the six interference scores are averaged to give the Pain Interference Score (PIS). Both the Pain and Interference criteria are assessed at baseline, following two injections of Zydax (14 days after commencement) and one week after the last of four injections of Zydax (day 28 of the study).

The clinical endpoint was analyzed using a reduction of more than 2.5 points in either the PSS or PIS (with the other criteria not increasing by more than 0.5 point) and no reduction in a general Quality of Life Score. 54 percent of dogs treated with Zydax and 35 percent of dogs on placebo met the clinical endpoint, producing a statistically significant outcome (p=0.01). 

"Based on this successful study, Zydax has the potential to be the first OA treatment to target the core deficit of osteoarthritis rather than just focusing on inflammation. Not only does Zydax have disease-modifying characteristics, it has a very safe profile over long-term use," said Robert Joseph, President and CEO of Parnell. "We feel confident, based on our strong pilot study results, that we have adequately assessed various efficacy assessment tools, including the CBPI and will be able to effectively design and complete a Pivotal Efficacy study appropriate for achieving registration of Zydax in major markets. We are excited about the imminent commencement of the Zydax pivotal efficacy trial in October 2014, with results anticipated in the first half of 2015."

Further objective evidence of the efficacy of Zydax treatment in reducing the clinical signs of osteoarthritis included:

  • A 43 percent improvement in the clinical signs of osteoarthritis was observed across all ten CBPI criteria for the Zydax treated group.
  • At Day 28, there was a significant difference between Zydax and placebo-treated animals for Pain at Worst (p-0.02), Interference with General Activity (p=0.02), Enjoyment of Life (p=0.04), Ability to Rise Up (p=0.04), Ability to Run (p=0.03), as well as for the PIS (p=0.03).
  • In addition to the CBPI efficacy model results, veterinarians conducted lameness examinations at baseline and at day 28. There was a significant difference between the Zydax and placebo groups for the criteria of Lameness Assessed at a Trot (p=0.03), as well as for Pain on Palpation (p=0.03).

About Zydax®

Zydax is Parnell's patented sulfate ester with disease-modifying characteristics for the treatment of OA in dogs and horses. Osteoarthritis is a slowly progressive and often severely degenerative joint disease. While currently available treatments for OA, such as anti-inflammatory drugs, ease the clinical signs of osteoarthritis for the short term. Zydax is designed to enable veterinarians and animal owners to safely and effectively manage the cause of OA over the life of the dog. Zydax targets the core deficit of OA by impacting both the anabolic and catabolic pathways of articular cartilage metabolism, stimulating the growth of new cartilage and inhibiting the Aggrecanase 1 enzyme, which is responsible for cartilage breakdown. Zydax is approved in Australia and New Zealand for the treatment of OA in dogs, and marketed in Asia and the Middle East for the treatment of OA in horses. With more than one-million doses sold, Zydax has led to the improved quality of life for dogs and improved performance of sport horses. 

About Parnell

Parnell (Nasdaq: PARN ) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions.  Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with proprietary software platforms - iKAM and mySYNCH. These innovative technology solutions are designed to enhance the quality of life or performance of animals, while driving customers' operational efficiency and profitability. Parnell believes its value-added solutions help establish them as a business partner with customers rather than only as a commodity provider, differentiating them from competitors.

For more information on the Company and its products, please visit www.parnell.com .

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of the U.S. Private Securities Reform Act of 1995. Words such as "may," "anticipate," "estimate," "expects," "projects," "intends," "plans," "develops," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. Forward-looking statements represent management's present judgment regarding future events and are subject to a number of risk and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding Parnell's research and development activities, its ability to conduct clinical trials of product candidates and the results of such trials, as well as risks and uncertainties relating to litigation, government regulation, economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on third parties, and other factors, including those described in Parnell's Form F-1 Registration Statement effective June 18, 2014. In light of these assumptions, risks, and uncertainties, the results and events discussed in the forward-looking statements contained in this press release might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Parnell is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise.

Robert Joseph, 816-654-3450

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 55

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 98

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 41

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 37

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 97

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 42

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 31

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 223

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 32

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 185

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading

Top 5 Most Recently Viewed Articles

Key Insights into Rathbones Group Plc's Position Disclosure

Updated Category News Views 171

Understanding Disclosure Requirements in Financial Markets In the world of finance and investments, transparency is paramount. Investors and market participants must be aware of regulations surrounding disclosure, especially when significant interest in relevant securities occurs. Here, we delve into key details surrounding a recent public disclosure by Rathbones Group...

Continue Reading
Atkore Inc. Announces Quarterly Cash Dividend for Shareholders

Updated Category News Views 139

Atkore Inc. Announces Cash Dividend for Shareholders Atkore Inc. (NYSE: ATKR), a prominent manufacturer known for its extensive electrical products, has informed its investors about the declaration of a quarterly cash dividend. This announcement signifies the company's ongoing commitment to providing value to its shareholders. The dividend is set at $0.32 per share of...

Continue Reading
Innovating Home Textiles: How CiCLO® is Changing Luxury Fabrics

Updated Category News Views 248

Innovative Technologies in Home Textiles An innovative fiber design blending renewable and biodegradable materials is advancing comfort, longevity, and responsible performance in premium home and hospitality textiles. At Heimtextil 2026, Intrinsic Advanced Materials will showcase a new generation of luxury textiles that embody sustainable practices, collaborating with...

Continue Reading
Vegan Food Industry Set for Huge Growth: USD 55.88 Billion by 2034

Updated Category News Views 271

Overview of the Vegan Food Market Growth The global vegan food market is anticipated to witness significant growth, increasing from USD 20.22 billion to an impressive USD 55.88 billion by 2034. This remarkable shift, with a compound annual growth rate (CAGR) of 10.7% from 2025 to 2034, reflects the rising consumer demand for plant-based options. Consumer Trends Driving...

Continue Reading
BAOS Stock Hits New Heights with Investor Enthusiasm

Updated Category News Views 190

BAOS Stock Surges to 52-Week High In a remarkable display of market confidence, Baosheng Media Group Holdings Limited (BAOS) has achieved a significant milestone by reaching a 52-week high of $7.33 per share. This surge demonstrates the strong backing from investors and the company's solid financial standing. Company Valuation and Financial Health The micro-cap company,...

Continue Reading